MA44226B1 - Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes - Google Patents

Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes

Info

Publication number
MA44226B1
MA44226B1 MA44226A MA44226A MA44226B1 MA 44226 B1 MA44226 B1 MA 44226B1 MA 44226 A MA44226 A MA 44226A MA 44226 A MA44226 A MA 44226A MA 44226 B1 MA44226 B1 MA 44226B1
Authority
MA
Morocco
Prior art keywords
group
hydrogen atom
benzo
dihydro
estrogen receptor
Prior art date
Application number
MA44226A
Other languages
English (en)
Inventor
Gary Mccort
Youssef El-Ahmad
Laurent Schio
Monsif Bouaboula
Maurice Brollo
Victor Certal
Bruno Filoche-Rommé
Frank Halley
Michel Tabart
Corinne Terrier
Fabienne Thompson
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA44226B1 publication Critical patent/MA44226B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne des composés de formule (i) : r1 et r2 représentent des atomes d'hydrogène ou de deutérium; r3 représente un atome d'hydrogène ou un groupe -cooh, -oh ou -opo(oh)2; r4 représente un atome d'hydrogène ou un atome de fluor; r5 représente un atome d'hydrogène ou un groupe -oh; au moins l'un de r3 ou r5 étant différent d'un atome d'hydrogène; quand r3 représente un groupe -cooh, -oh ou -opo(oh)2, alors r5 représente un atome d'hydrogène; quand r5 représente un groupe -oh, alors r3 et r4 représentent des atomes d'hydrogène; et r6 est choisi parmi un groupe phényle, hétéroaryle, cycloalkyle ou hétérocycloalkyle éventuellement substitué. L'invention concerne également la préparation et les utilisations thérapeutiques des composés de formule (i) en tant qu'inhibiteurs et agents de dégradation de récepteurs des œstrogènes, utilisés en particulier pour le traitement du cancer.
MA44226A 2016-02-15 2017-02-14 Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes MA44226B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305174 2016-02-15
PCT/EP2017/053282 WO2017140669A1 (fr) 2016-02-15 2017-02-14 Dérivés de 6,7-dihydro-5h-benzo[7]annulène utilisés en tant que modulateurs de récepteurs des oestrogènes

Publications (1)

Publication Number Publication Date
MA44226B1 true MA44226B1 (fr) 2021-07-29

Family

ID=55398242

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44226A MA44226B1 (fr) 2016-02-15 2017-02-14 Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes
MA046479A MA46479A (fr) 2016-02-15 2017-02-14 Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046479A MA46479A (fr) 2016-02-15 2017-02-14 Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène

Country Status (37)

Country Link
US (6) US9714221B1 (fr)
EP (2) EP3416962B1 (fr)
JP (4) JP6425852B1 (fr)
KR (2) KR20220098057A (fr)
CN (2) CN108884079B (fr)
AR (1) AR107616A1 (fr)
AU (2) AU2017221083B2 (fr)
BR (1) BR112018016490A2 (fr)
CA (1) CA3014424A1 (fr)
CL (1) CL2018002290A1 (fr)
CO (1) CO2018009534A2 (fr)
CR (1) CR20180442A (fr)
CY (1) CY1125165T1 (fr)
DK (2) DK3524600T3 (fr)
DO (1) DOP2018000184A (fr)
EA (2) EA038639B1 (fr)
EC (1) ECSP18069466A (fr)
ES (2) ES2881508T3 (fr)
HR (1) HRP20211043T1 (fr)
HU (2) HUE055107T2 (fr)
IL (2) IL261099B (fr)
LT (1) LT3416962T (fr)
MA (2) MA44226B1 (fr)
MX (2) MX2020011469A (fr)
MY (1) MY196486A (fr)
PE (1) PE20181893A1 (fr)
PH (1) PH12018501679A1 (fr)
PL (1) PL3416962T3 (fr)
PT (1) PT3416962T (fr)
RS (1) RS62132B1 (fr)
SG (2) SG11201806829TA (fr)
SI (1) SI3416962T1 (fr)
TN (1) TN2018000285A1 (fr)
TW (3) TWI737681B (fr)
UY (1) UY37124A (fr)
WO (1) WO2017140669A1 (fr)
ZA (1) ZA201805137B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3416962B1 (fr) * 2016-02-15 2021-05-05 Sanofi Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes
SG11201903908PA (en) * 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP3434272A1 (fr) 2017-07-25 2019-01-30 Sanofi Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique
JP7348665B2 (ja) * 2018-02-06 2023-09-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体
CA3109090A1 (fr) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Methodes diagnostiques et therapeutiques pour le traitement du cancer du sein
WO2020049150A1 (fr) * 2018-09-07 2020-03-12 Sanofi Sels de méthyl 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl] oxyphényl]-8,9-dihydro-7 h-benzo[7]annulène-2-carboxylate et leur procédé de préparation
EP3699167A1 (fr) 2019-02-22 2020-08-26 Sanofi Procédé de préparation de méthyl 1-benzosuberone-7-carboxylate
JP2022531898A (ja) 2019-05-09 2022-07-12 サノフイ 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸
KR102058384B1 (ko) * 2019-09-06 2019-12-24 강원대학교산학협력단 2h-벤조[7]에눌렌 화합물 및 이의 제조방법
CN114502562A (zh) * 2019-10-01 2022-05-13 赛诺菲 新颖的经取代的6,7-二氢-5h-苯并[7]轮烯化合物、其制备方法以及其治疗用途
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN113896669A (zh) * 2020-06-22 2022-01-07 江苏先声药业有限公司 雌激素受体调节剂及其用途
WO2022001971A1 (fr) * 2020-06-28 2022-01-06 南京明德新药研发有限公司 Composé cyclique fusionné à l'indazole
KR20230092971A (ko) 2020-10-19 2023-06-26 사노피 신규한 치환 6,7-디히드로-5h-벤조[7]아눌렌 유도체, 이의 제조 방법 및 이의 치료적 용도
WO2022084298A1 (fr) 2020-10-19 2022-04-28 Sanofi Composés de 6,7-dihydro-5h-benzo[7]annulène substitués, leurs dérivés, procédés permettant leur préparation et utilisations thérapeutiques associées
US20240002950A1 (en) 2020-11-23 2024-01-04 Sanofi Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer
MX2023006020A (es) * 2020-11-23 2023-06-08 Sanofi Sa Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.
WO2022166879A1 (fr) * 2021-02-04 2022-08-11 正大天晴药业集团股份有限公司 Composé bifonctionnel à cycle benzo à sept chaînons et son application
TW202304424A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
TW202304425A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202313558A (zh) * 2021-07-08 2023-04-01 大陸商勤浩醫藥(蘇州)有限公司 一類苯并七元環類化合物及其應用
WO2023287938A1 (fr) 2021-07-15 2023-01-19 Teva Pharmaceuticals International Gmbh Formes à l'état solide d'amcenestrant
WO2023125700A1 (fr) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 Forme saline et forme cristalline d'un composé de tétrahydrocyclohepta indazole
TW202400136A (zh) 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
WO2023187086A1 (fr) 2022-03-31 2023-10-05 Sanofi Forme solide amorphe d'amcenestrant
WO2023198904A1 (fr) 2022-04-15 2023-10-19 Sanofi Dérivés de 6,7-dihydro-5h-benzo[7]annulène substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2023198907A1 (fr) 2022-04-15 2023-10-19 Sanofi Dérivés de 6,7-dihydro-5h-benzo[7]annulène substitués, procédés pour leur préparation et utilisations thérapeutiques associées
WO2023198905A1 (fr) 2022-04-15 2023-10-19 Sanofi Nouveaux composés de de vinyl-n-propyl-pyrrolidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2023198901A1 (fr) 2022-04-15 2023-10-19 Sanofi Nouveaux dérivés de 4-amino-4-oxo-but-2-ényle substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2023198879A1 (fr) 2022-04-15 2023-10-19 Sanofi Nouveaux composés de n-propyl-pyrrolidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2023198903A1 (fr) 2022-04-15 2023-10-19 Sanofi Nouveaux composés de n-propyl-pyrrolidine et de n-propyl-azétidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2024006776A1 (fr) * 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Agents de dégradation des récepteurs alpha des oestrogènes et leur utilisation médicale
WO2024042185A1 (fr) 2022-08-25 2024-02-29 Sanofi Nouveaux dérivés d'acide tétrahydroisoquinoléine-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2024042163A1 (fr) 2022-08-25 2024-02-29 Sanofi Nouveaux dérivés d'acide 2,3,4,9-tétrahydro-1h-pyrido[3,4-b]indole carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2024042152A1 (fr) 2022-08-25 2024-02-29 Sanofi Nouveaux dérivés d'acide 2-carbonyl-benzothiophene-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2024042157A1 (fr) 2022-08-25 2024-02-29 Sanofi Nouveaux dérivés d'acide carboxylique de quinoléine et de tétrahydronaphtalène substitués et leurs utilisations thérapeutiques
WO2024042187A1 (fr) 2022-08-25 2024-02-29 Sanofi Nouveaux dérivés d'acide benzothiophène-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2024052518A1 (fr) 2022-09-09 2024-03-14 Sanofi Dérivés de tétrahydrocyclohepta[e]indole substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2024100236A1 (fr) 2022-11-11 2024-05-16 Astrazeneca Ab Polythérapies pour le traitement du cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1752792A (en) * 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286893T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
CZ2004220A3 (cs) * 2001-08-11 2004-06-16 Bristol-Myers Squibb Pharma Company Název neuveden
ES2350446T3 (es) 2002-04-24 2011-01-24 MERCK SHARP & DOHME CORP. Moduladores de los receptores de estrógenos.
JP4500689B2 (ja) * 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
BRPI0413923A (pt) * 2003-08-29 2006-11-07 Ono Pharmaceutical Co composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo
WO2006012135A1 (fr) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Antagonistes de ccr2 a base de sels quaternaires
US20050288238A1 (en) * 2004-06-28 2005-12-29 Pfizer Inc Benzocyclodecane derivatives with antitumor activity
DE102005014090A1 (de) * 2005-03-22 2006-09-28 Schering Ag 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
WO2006138427A2 (fr) 2005-06-14 2006-12-28 Baylor University Analogues combrestatiniques a activite de liaison avec la tubuline
EP2048126A1 (fr) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Dérivés de benzocycloheptanes en tant qu'oestrogènes actifs de manière sélective
EP2090579A1 (fr) * 2008-01-29 2009-08-19 Sanofi-Aventis Dérivés d'hétéroarylamide diazépinopyrimidone substitués
DE102010030538A1 (de) * 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012068284A2 (fr) * 2010-11-16 2012-05-24 Baylor University Procédé efficace de préparation de benzosubérènes fonctionnalisés
TW201329025A (zh) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2861939A1 (fr) * 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Nouveaux derives d'arylalcene et utilisation de ceux-ci en tant que modulateurs selectifs de recepteur d'oestrogene
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
JP2016511247A (ja) * 2013-02-19 2016-04-14 バイエル ファーマ アクチエンゲゼルシャフト ビシクロ２，３−ベンゾジアゼピン類及びスピロ環式置換２，３−ベンゾジアゼピン類
WO2015028409A1 (fr) * 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft Dérivés de 6,7-dihydro-5h-benzo[7]annulène, procédé pour les préparer, préparations pharmaceutiques les contenant et leur utilisation pour fabriquer des médicaments
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
BR112017023269A2 (pt) 2015-04-29 2018-11-06 Radius Pharmaceuticals Inc métodos para tratamento de câncer
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
EP3416962B1 (fr) 2016-02-15 2021-05-05 Sanofi Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes
SG11201903908PA (en) 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
ZA201805137B (en) 2023-09-27
ES2906208T3 (es) 2022-04-13
IL261099B (en) 2020-10-29
HUE055107T2 (hu) 2021-10-28
US10570090B2 (en) 2020-02-25
US20170233340A1 (en) 2017-08-17
TW202138349A (zh) 2021-10-16
US20210323916A1 (en) 2021-10-21
EA038639B1 (ru) 2021-09-28
SI3416962T1 (sl) 2021-08-31
EP3416962B1 (fr) 2021-05-05
ECSP18069466A (es) 2018-09-30
DK3524600T3 (da) 2022-02-07
CY1125165T1 (el) 2023-06-09
EP3524600B1 (fr) 2021-11-17
TW202138348A (zh) 2021-10-16
EP3524600A1 (fr) 2019-08-14
US11214541B2 (en) 2022-01-04
AU2021225215B2 (en) 2023-05-25
TWI779621B (zh) 2022-10-01
KR20180105759A (ko) 2018-09-28
JP2019031537A (ja) 2019-02-28
MX2020011469A (es) 2021-09-30
UY37124A (es) 2017-09-29
CL2018002290A1 (es) 2018-10-05
PT3416962T (pt) 2021-07-23
LT3416962T (lt) 2021-07-12
US20180079720A1 (en) 2018-03-22
EA202090255A3 (ru) 2020-07-31
KR20220098057A (ko) 2022-07-08
EA201891841A1 (ru) 2019-01-31
PE20181893A1 (es) 2018-12-11
HUE057892T2 (hu) 2022-06-28
US9714221B1 (en) 2017-07-25
AR107616A1 (es) 2018-05-16
JP6425852B1 (ja) 2018-11-21
MX2018009908A (es) 2018-09-07
SG11201806829TA (en) 2018-09-27
JP6476343B2 (ja) 2019-02-27
EA034994B1 (ru) 2020-04-15
WO2017140669A1 (fr) 2017-08-24
ES2881508T3 (es) 2021-11-29
CA3014424A1 (fr) 2017-08-24
CN108884079A (zh) 2018-11-23
JP2019081776A (ja) 2019-05-30
JP2018537406A (ja) 2018-12-20
PL3416962T3 (pl) 2021-11-22
TN2018000285A1 (en) 2020-01-16
EP3416962A1 (fr) 2018-12-26
US20200392081A1 (en) 2020-12-17
RS62132B1 (sr) 2021-08-31
JP2020128385A (ja) 2020-08-27
US20220073460A1 (en) 2022-03-10
US20240150284A1 (en) 2024-05-09
CN112979524A (zh) 2021-06-18
TWI779620B (zh) 2022-10-01
EA202090255A2 (ru) 2020-05-31
IL277750B (en) 2022-06-01
SG10202106024XA (en) 2021-07-29
CN108884079B (zh) 2021-03-05
AU2017221083B2 (en) 2021-06-24
MY196486A (en) 2023-04-17
DK3416962T3 (da) 2021-07-26
JP6695457B2 (ja) 2020-05-20
CR20180442A (es) 2018-12-21
JP6868142B2 (ja) 2021-05-12
TWI737681B (zh) 2021-09-01
CO2018009534A2 (es) 2018-09-20
TW201741285A (zh) 2017-12-01
IL261099A (en) 2018-10-31
DOP2018000184A (es) 2019-01-31
AU2017221083A1 (en) 2018-10-04
BR112018016490A2 (pt) 2018-12-18
IL277750A (en) 2020-11-30
PH12018501679A1 (en) 2019-06-10
HRP20211043T1 (hr) 2021-10-01
AU2021225215A1 (en) 2021-09-30
MA46479A (fr) 2019-08-14

Similar Documents

Publication Publication Date Title
MA44226B1 (fr) Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes
MA27573A1 (fr) Sinomenine et derives de sinomenine, synthese et utilisation.
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
FR2391999A1 (fr) Derives de cyclohexane a utiliser comme herbicides selectifs
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA38647B1 (fr) Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
ATE195247T1 (de) Chelat-zubereitung, die alpha-diamin-verbindungen enthalten
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
CA2397636A1 (fr) Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique
MA47102B1 (fr) Dérivés de pyrane en tant qu'inhibiteurs de cyp11a1 (cytochrome p450 monooxygénase 11a1)
FR3115207B1 (fr) Utilisation de composés thiopyridinones pour prévenir la formation des points noirs cutanés
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
EP4257137A3 (fr) Dérivés de carbamoylpyridone polycycliques pour le traitement du vih
MA29239B1 (fr) Derives de n- (heteroaryl) -1h-ind0le-2-carb0xamids et leur utilisation comme ligands du recepteur vanilloide trpv1
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
RU2012134454A (ru) Агент для профилактики или уменьшения пигментации
FR2374903A1 (fr) Nouvelle association utilisable en medecine veterinaire
MA38659A1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate
FR3039767B1 (fr) Composition destinee a vectoriser un agent anticancereux
FR3097223B1 (fr) Adduits silylés, polymères silylés et compositions les comprenant
KR940701260A (ko) 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법